← All trials
NCT04387981
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 21, 2020
- Primary completion
- Jun 19, 2020
- Completion date
- Jun 19, 2020
- First posted
- May 14, 2020
- Last posted
- May 14, 2020
- Enrollment
- 6
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- NeRRe Therapeutics Ltd.Lead sponsor
- QuotientOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.